Research programme: human blood coagulation factors - Glycotope/ Octapharma

Drug Profile

Research programme: human blood coagulation factors - Glycotope/ Octapharma

Alternative Names: FVII-GEX

Latest Information Update: 30 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glycotope
  • Developer Glycotope; Octapharma
  • Class Coagulants; Recombinant proteins
  • Mechanism of Action Factor VIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 30 Nov 2015 Glycotope and Octapharma agree to co-develop human blood coagulation factors in Germany and Switzerland for Coagulation disorders
  • 08 Oct 2015 Preclinical trials in Haemophilia in Germany (unspecified route)
  • 08 Oct 2015 Preclinical trials in Haemophilia in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top